{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:50:19Z","timestamp":1794199819274,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated 2445 CKD patients (2010\u20132012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels &lt;\u2009100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221\u20130.808,<jats:italic>p<\/jats:italic>\u00a0=\u20090.009).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-021-02313-1","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T22:03:57Z","timestamp":1616709837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Jos\u00e9 Luis","family":"Gorriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"D\u2019Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Puchades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayara","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonay","family":"Pantoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Montomoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Llisterri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Pallares-Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Valdivielso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"2313_CR1","doi-asserted-by":"crossref","unstructured":"Saran R, Robinson B, Abbott KC, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;19.","DOI":"10.1053\/j.ajkd.2019.09.003"},{"key":"2313_CR2","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, Mcculloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351 Available from: www.nejm.org.","DOI":"10.1056\/NEJMoa041031"},{"key":"2313_CR3","doi-asserted-by":"crossref","unstructured":"Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, et al. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2018;13(3).","DOI":"10.1371\/journal.pone.0192895"},{"key":"2313_CR4","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant. 2014;29:iv15\u201325.","journal-title":"Nephrol Dial Transplant"},{"key":"2313_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ekir.2019.12.007","volume":"5","author":"IY Kuo","year":"2020","unstructured":"Kuo IY, Chapman AB. Polycystins, ADPKD, and cardiovascular disease. Kidney Int Rep. 2020;5:396\u2013406 Elsevier Inc.","journal-title":"Kidney Int Rep"},{"key":"2313_CR6","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez V, Comas J, Arcos E, D\u00edaz JM, Muray S, Cabezuelo J, et al. Renal replacement therapy in ADPKD patients: A 25-year survey based on the Catalan registry. BMC Nephrol. 2013;14(1).","DOI":"10.1186\/1471-2369-14-186"},{"key":"2313_CR7","doi-asserted-by":"crossref","unstructured":"Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS ONE. 2017;12(10).","DOI":"10.1371\/journal.pone.0186665"},{"key":"2313_CR8","series-title":"The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study","volume-title":"Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain","author":"M Junyent","year":"2010","unstructured":"Junyent M, Mart\u00ednez M, Borr\u00e0s M, Coll B, Valdivielso JM, Vidal T, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. 2010. Available from: http:\/\/www.nefrona.es."},{"key":"2313_CR9","doi-asserted-by":"crossref","unstructured":"Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fern\u00e1ndez E. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014;15(1).","DOI":"10.1186\/1471-2369-15-168"},{"issue":"24","key":"2313_CR10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1402686.","journal-title":"N Engl J Med"},{"key":"2313_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019314595. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2313_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/ajkd.2001.27720","volume":"38","author":"RD Perrone","year":"2001","unstructured":"Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001;38(4):777\u201384. https:\/\/doi.org\/10.1053\/ajkd.2001.27720.","journal-title":"Am J Kidney Dis"},{"key":"2313_CR13","doi-asserted-by":"crossref","unstructured":"Chirumamilla R, Mina D, Siyahian S, MPark. Subclinical metabolic and cardiovascular abnormalities in autosomal dominant polycystic kidney disease. 2018;90:237\u201345.","DOI":"10.5414\/CN109233"},{"issue":"49","key":"2313_CR14","doi-asserted-by":"publisher","first-page":"e5595","DOI":"10.1097\/MD.0000000000005595","volume":"95","author":"L Sans","year":"2016","unstructured":"Sans L, Pascual J, Radosevic A, Quintian C, Ble M, Molina L, et al. Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients. Medicine. 2016;95(49):e5595.","journal-title":"Medicine"},{"key":"2313_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrneph.2009.13","volume":"5","author":"T Ecder","year":"2009","unstructured":"Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009;5:221\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2313_CR16","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1159\/000495638","volume":"43","author":"B Yang","year":"2018","unstructured":"Yang B, Wang Q, Wang R, Xu T. Clinical manifestation, management and prognosis of acute myocardial infarction in autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2018;43(6):1806\u201312. https:\/\/doi.org\/10.1159\/000495638.","journal-title":"Kidney Blood Press Res"},{"key":"2313_CR17","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399\u2013418 American Society of Nephrology.","journal-title":"J Am Soc Nephrol"},{"key":"2313_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31:337\u201348 Oxford University Press.","journal-title":"Nephrol Dial Transplant"},{"key":"2313_CR19","doi-asserted-by":"crossref","unstructured":"Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, et al. Determinants of progression in early autosomal dominant polycystic kidney disease: is it blood pressure or renin-angiotensin-aldosterone- system blockade? Curr Hypertens Rev. 2018;14(1).","DOI":"10.2174\/1573402114666180322110209"},{"key":"2313_CR20","doi-asserted-by":"crossref","unstructured":"Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017;91(2).","DOI":"10.1016\/j.kint.2016.10.018"},{"key":"2313_CR21","first-page":"1","volume-title":"Oxford textbook of clinical nephrology","author":"P Raggi","year":"2015","unstructured":"Raggi P, D\u2019Marco L. Imaging for detection of vascular disease in chronic kidney disease patients. In: Oxford textbook of clinical nephrology. 4th ed; 2015. p. 1\u201323. Available from: http:\/\/www.oxfordmedicine.com\/view\/10.1093\/med\/9780199592548.001.0001\/med-9780199592548.","edition":"4"},{"issue":"5","key":"2313_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/j.ajkd.2004.01.011","volume":"43","author":"O Kocaman","year":"2004","unstructured":"Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2004;43(5):854\u201360. https:\/\/doi.org\/10.1053\/j.ajkd.2004.01.011.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2313_CR23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2215\/CJN.02330607","volume":"3","author":"K Turkmen","year":"2008","unstructured":"Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A, Kasikcioglu E, et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol. 2008;3(4):986\u201391. https:\/\/doi.org\/10.2215\/CJN.02330607.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2313_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1440-1797.2008.01049.x","volume":"14","author":"S Rong","year":"2009","unstructured":"Rong S, Jin X, Ye C, Chen J, Mei C. Carotid vascular remodelling in patients with autosomal dominant polycystic kidney disease. Nephrology. 2009;14(1):113\u20137. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.01049.x.","journal-title":"Nephrology."},{"key":"2313_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.12659\/MSM.889857","volume":"20","author":"I Salk","year":"2014","unstructured":"Salk I, Yildiz G, Egilmez H, Atalar MH, Candan F, Cetin A. Carotid artery Doppler ultrasonography in patients with chronic kidney disease. Med Sci Monit. 2014;20:11\u20137.","journal-title":"Med Sci Monit"},{"issue":"4","key":"2313_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1159\/000492244","volume":"43","author":"M Coban","year":"2018","unstructured":"Coban M, Inci A, Yllmaz U, Asilturk E. The association of fibroblast growth factor 23 with arterial stiffness and atherosclerosis in patients with autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2018;43(4):1160\u201373. https:\/\/doi.org\/10.1159\/000492244.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"2313_CR27","first-page":"52","volume":"53","author":"L D\u2019Marco","year":"2012","unstructured":"D\u2019Marco L, Garc\u00eda I, Vega C. Acido \u00farico, aterosclerosis y calcificaciones vasculares en enfermedad renal cr\u00f3nica. Investig Clin. 2012;53(1):52\u20139.","journal-title":"Investig Clin"},{"issue":"3","key":"2313_CR28","first-page":"513","volume":"32","author":"D Arroyo","year":"2017","unstructured":"Arroyo D, Betriu A, Valls J, Gorriz JL, Pallares V, Abajo M, et al. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. Nephrol Dial Transplant. 2017;32(3):513\u201320.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2313_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1681\/ASN.2014020173","volume":"26","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26(2):439\u201347. https:\/\/doi.org\/10.1681\/ASN.2014020173.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2313_CR30","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1159\/000486011","volume":"42","author":"S Lai","year":"2017","unstructured":"Lai S, Mastroluca D, Matino S, Panebianco V, Vitarelli A, Capotosto L, et al. Early markers of cardiovascular risk in autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2017;42(6):1290\u2013302. https:\/\/doi.org\/10.1159\/000486011.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"2313_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2215\/CJN.03250410","volume":"6","author":"VE Torres","year":"2011","unstructured":"Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(3):640\u20137. https:\/\/doi.org\/10.2215\/CJN.03250410.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2313_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","volume":"23","author":"M Bermudez-Lopez","year":"2019","unstructured":"Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, et al. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Expert Opin Ther Targets. 2019;23(7):619\u201330. https:\/\/doi.org\/10.1080\/14728222.2019.1620206.","journal-title":"Expert Opin Ther Targets"},{"key":"2313_CR33","doi-asserted-by":"crossref","unstructured":"Kim K, Trott JF, Gao G, Chapman A, Weiss RH. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019;20(1).","DOI":"10.1186\/s12882-019-1249-6"},{"key":"2313_CR34","doi-asserted-by":"crossref","unstructured":"Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GFM. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2015;2015 John Wiley and Sons Ltd.","DOI":"10.1002\/14651858.CD010294.pub2"},{"key":"2313_CR35","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2215\/CJN.03960318","volume":"13","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13:1765\u201376 American Society of Nephrology.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2313_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 1;41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"2313_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388 Oxford University Press.","journal-title":"Eur Heart J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02313-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02313-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02313-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T13:25:04Z","timestamp":1671715504000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02313-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02313-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed the informed consent, and the study protocol was approved by the Ethics Committee of the Arnau de Vilanova University Hospital. All the study was conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declares no competing interests in this investigation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}